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Introduction
In the decade since the first approval of interferon beta-
1b (Betaferon®) for relapsing-remitting (RR) multiple
sclerosis (MS), considerable progress has been made in
understanding the pathological mechanisms underly-
ing MS and developing strategies to maximise the effi-
cacy of existing therapies. The papers presented in this
supplement represent much of the current thinking in
the field of MS,as presented at a 1-day meeting in Vienna
in March 2002.The purpose of the meeting,entitled New
Aspects in the Treatment of Multiple Sclerosis with
Betaferon®, was to discuss the current status of MS re-
search and treatment and highlight some of the existing
challenges for future MS diagnosis and disease manage-
ment.
The present thinking on the pathogenetic mecha-
nisms responsible for tissue damage is outlined, as are
the latest developments in magnetic resonance imaging
(MRI) techniques. The development of new MRI tech-
niques addresses the need for better, more clinically rel-
evant outcome measures, and has already increased our
understanding of MS pathology and improved diagno-
sis. In terms of treatment, the data suggesting that treat-
ing patients after the first clinical event (clinically iso-
lated syndrome) can produce some benefit are
reviewed, as are outstanding questions, such as the long-
term effects of early treatment, and early high-dose fre-
quent interferon beta therapy – questions that are to be
addressed by the BENEFIT (BEtaferon in Newly Emerg-
ing multiple sclerosis For Initial Treatment) study. Fi-
nally, the important role of neurorehabilitation and its
effects on quality of life are discussed.
While there are still many unanswered questions in
MS therapy, the progress to date gives cause for opti-
mism that current basic research and clinical trials will
provide greater benefits for patients in the future.
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